BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990;81:301-305. [PMID: 2117510 DOI: 10.1111/j.1365-2249.1990.tb03334.x] [Cited by in Crossref: 306] [Cited by in F6Publishing: 320] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental Colitis Impairs Linear Bone Growth Independent of Nutritional Factors: . Journal of Pediatric Gastroenterology & Nutrition 1997;25:137-41. [DOI: 10.1097/00005176-199708000-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis]
2 Grimm MC. New and emerging therapies for inflammatory bowel diseases. Journal of Gastroenterology and Hepatology 2009;24:S69-74. [DOI: 10.1111/j.1440-1746.2009.06074.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
3 López-Posadas R, Neurath MF, Atreya I. Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cell Mol Life Sci 2017;74:803-26. [PMID: 27624395 DOI: 10.1007/s00018-016-2363-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
4 Roda G, Sartini A, Zambon E, Calafiore A, Marocchi M, Caponi A, Belluzzi A, Roda E. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol. 2010;16:4264-4271. [PMID: 20818809 DOI: 10.3748/wjg.v16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Markovic BS, Kanjevac T, Harrell CR, Gazdic M, Fellabaum C, Arsenijevic N, Volarevic V. Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases. Stem Cell Rev and Rep 2018;14:153-65. [DOI: 10.1007/s12015-017-9789-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
6 Monteleone G, Pallone F, Caprioli F. Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opin Investig Drugs 2013;22:1123-32. [PMID: 23802627 DOI: 10.1517/13543784.2013.813931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8:600-609. [PMID: 20117244 DOI: 10.1016/j.cgh.2010.01.014] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
8 MacDonald TT, Murch SH. Aetiology and pathogenesis of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol. 1994;8:1-34. [PMID: 8003737 DOI: 10.1016/s0950-3528(06)80017-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
9 Obermeier F, Kojouharoff G, Hans W, Schölmerich J, Gross V, Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol. 1999;116:238-245. [PMID: 10337013 DOI: 10.1046/j.1365-2249.1999.00878.x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 211] [Article Influence: 9.2] [Reference Citation Analysis]
10 Marx D, Tassabehji M, Heer S, Hüttenbrink KB, Szelenyi I. Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther 2002;15:7-15. [PMID: 11969359 DOI: 10.1006/pupt.2001.0315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
11 Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance: IV IRON IN ANEMIA MANAGEMENT. Transfusion 2008;48:988-1000. [DOI: 10.1111/j.1537-2995.2007.01633.x-i2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Sakisaka H, Takedatsu H, Mitsuyama K, Mochizuki S, Sakurai K, Sakisaka S, Hirai F. Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation. Int J Mol Sci 2020;21:E683. [PMID: 31968666 DOI: 10.3390/ijms21020683] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Hodgson HJF, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 1991;5:555-84. [DOI: 10.1111/j.1365-2036.1991.tb00525.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
14 Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol. 1996;15:435-439. [PMID: 8894355 DOI: 10.1007/bf02229639] [Cited by in Crossref: 34] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
15 Parhar K, Morse J, Salh B. The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int J Colorectal Dis 2007;22:601-9. [PMID: 17009010 DOI: 10.1007/s00384-006-0193-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
16 Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002;61 Suppl 2:ii19-24. [PMID: 12379615 DOI: 10.1136/ard.61.suppl_2.ii19] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
18 John LJ, Fromm M, Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal. 2011;15:1255-1270. [PMID: 21294654 DOI: 10.1089/ars.2011.3892] [Cited by in Crossref: 113] [Cited by in F6Publishing: 109] [Article Influence: 10.3] [Reference Citation Analysis]
19 Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, Masuda J, Handa K, Harada K, Nishida H, Toyonaga A, Sata M. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005;141:130-40. [PMID: 15958079 DOI: 10.1111/j.1365-2249.2005.02825.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
20 Kang EA, Choi HI, Hong SW, Kang S, Jegal HY, Choi EW, Park BS, Kim JS. Extracellular Vesicles Derived from Kefir Grain Lactobacillus Ameliorate Intestinal Inflammation via Regulation of Proinflammatory Pathway and Tight Junction Integrity. Biomedicines 2020;8:E522. [PMID: 33233771 DOI: 10.3390/biomedicines8110522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RP. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 1993;34:252-6. [PMID: 8094364 DOI: 10.1136/gut.34.2.252] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.2] [Reference Citation Analysis]
22 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58. [PMID: 24444171 DOI: 10.1111/apt.12624] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 13.1] [Reference Citation Analysis]
23 Ahluwalia JP. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012;96:525-44. [DOI: 10.1016/j.mcna.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
24 Stronkhorst A, Tytgat GNJ, Van Deventer SJH. CD4 Antibody Treatment in Crohn's Disease. Scandinavian Journal of Gastroenterology 2009;27:61-5. [DOI: 10.3109/00365529209096029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
26 Ye MB, Bak JP, An CS, Jin HL, Kim JM, Kweon HJ, Choi DK, Park PJ, Kim YJ, Lim BO. Dietary β-glucan regulates the levels of inflammatory factors, inflammatory cytokines, and immunoglobulins in interleukin-10 knockout mice. J Med Food 2011;14:468-74. [PMID: 21434779 DOI: 10.1089/jmf.2010.1197] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
27 Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379-383. [PMID: 17545772 DOI: 10.1097/mog.0b013e32816aa392] [Cited by in Crossref: 207] [Cited by in F6Publishing: 107] [Article Influence: 13.8] [Reference Citation Analysis]
28 Hong T, Jin G, Yoshino G, Miura M, Maeda Y, Cho S, Cyong J. Protective effects of Polygalae root in experimental TNBS-induced colitis in mice. Journal of Ethnopharmacology 2002;79:341-6. [DOI: 10.1016/s0378-8741(01)00399-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Ebert EC. Giardia induces proliferation and interferon gamma production by intestinal lymphocytes. Gut 1999;44:342-6. [PMID: 10026318 DOI: 10.1136/gut.44.3.342] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
30 Ford AC, Peyrin-biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology 2013;108:1268-76. [DOI: 10.1038/ajg.2013.138] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 25.1] [Reference Citation Analysis]
31 Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:83-100. [PMID: 8003745 DOI: 10.1016/s0950-3528(06)80020-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
32 Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest 2008;88:1110-20. [PMID: 18711353 DOI: 10.1038/labinvest.2008.78] [Cited by in Crossref: 192] [Cited by in F6Publishing: 191] [Article Influence: 13.7] [Reference Citation Analysis]
33 Cole AT, Hawkey CJ. Treatment of inflammatory bowel disease from now to the millennium. Baillieres Clin Gastroenterol 1994;8:351-79. [PMID: 7949463 DOI: 10.1016/0950-3528(94)90009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
34 Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008;1:175-82. [DOI: 10.1038/mi.2008.7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
35 Ruemmele F, Gurbindo C, Mansour A, Marchand R, Levy E, Seidman E. Effects of Interferon γ on growth, apoptosis, and MHC class II expression of immature rat intestinal crypt (IEC-6) cells. J Cell Physiol 1998;176:120-6. [DOI: 10.1002/(sici)1097-4652(199807)176:1<120::aid-jcp14>3.0.co;2-b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
36 Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992;339:381-5. [PMID: 1346658 DOI: 10.1016/0140-6736(92)90077-g] [Cited by in Crossref: 110] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
37 Villanacci V, Cadei M, Lanzarotto F, Ricci C, Antonelli E, Cannatelli R, Gulotta T, Fontana L, Pasquali V, Sigala S, Salviato T, Nascimbeni R, Bassotti G. Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Ann Diagn Pathol 2019;38:20-5. [PMID: 30388432 DOI: 10.1016/j.anndiagpath.2018.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Galka E, Thompson JL, Zhang WJ, Poritz LS, Koltun WA. Stat6null phenotype human lymphocytes exhibit increased apoptosis. Journal of Surgical Research 2004;122:14-20. [DOI: 10.1016/j.jss.2004.05.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
39 Gustafson-Svärd C, Tagesson C, Boll RM, Kald B. Tumor necrosis factor-alpha potentiates phospholipase A2-stimulated release and metabolism of arachidonic acid in cultured intestinal epithelial cells (INT 407). Scand J Gastroenterol 1993;28:323-30. [PMID: 8488366 DOI: 10.3109/00365529309090250] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
40 Kandil HM, Berschneider HM, Argenzio RA. Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. Gut 1994;35:934-40. [PMID: 8063221 DOI: 10.1136/gut.35.7.934] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 2.2] [Reference Citation Analysis]
41 Liang GH, Weber CR. Molecular aspects of tight junction barrier function. Curr Opin Pharmacol. 2014;19:84-89. [PMID: 25128899 DOI: 10.1016/j.coph.2014.07.017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
42 Min JK, Lee CH, Jang SE, Park JW, Lim SJ, Kim DH, Bae H, Kim HJ, Cha JM. Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. J Gastroenterol Hepatol 2015;30:858-65. [PMID: 25311527 DOI: 10.1111/jgh.12812] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
43 Macdermott RP. The Role of the Mucosal Immune System in Inflammatory Bowel Disease. Essentials of Mucosal Immunology. Elsevier; 1996. pp. 321-39. [DOI: 10.1016/b978-012394330-9/50026-0] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
44 Nedelkopoulou N, Vadamalayan B, Vergani D, Mieli-vergani G. Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2018;66:100-5. [DOI: 10.1097/mpg.0000000000001759] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
45 Van Damme N, De Keyser F, Demetter P, Baeten D, Mielants H, Verbruggen G, Cuvelier C, Veys EM, De Vos M. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol. 2001;125:383-390. [PMID: 11531945 DOI: 10.1046/j.1365-2249.2001.01638.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
46 Trepicchio WL, Dorner AJ. The therapeutic utility of Interleukin-11 in the treatment of inflammatory disease. Expert Opin Investig Drugs. 1998;7:1501-1504. [PMID: 15992047 DOI: 10.1517/13543784.7.9.1501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
47 van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135. [PMID: 7797011 DOI: 10.1016/0016-5085(95)90277-5] [Cited by in Crossref: 739] [Cited by in F6Publishing: 681] [Article Influence: 27.4] [Reference Citation Analysis]
48 Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH; Schering Plough (Australia). Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001;31:146-50. [PMID: 11478343 DOI: 10.1046/j.1445-5994.2001.00039.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
49 Autschbach F, Schürmann G, Qiao L, Merz H, Wallich R, Meuer SC. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Arch 1995;426:51-60. [PMID: 7704324 DOI: 10.1007/BF00194698] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
50 Günther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. 2013;62:1062-1071. [PMID: 22689519 DOI: 10.1136/gutjnl-2011-301364] [Cited by in Crossref: 206] [Cited by in F6Publishing: 202] [Article Influence: 20.6] [Reference Citation Analysis]
51 Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. [PMID: 12047962 DOI: 10.1016/s0140-6736(02)08512-4] [Cited by in Crossref: 2805] [Cited by in F6Publishing: 777] [Article Influence: 140.3] [Reference Citation Analysis]
52 Facklis K, Plevy SE, Vasiliauskas EA, Kam L, Taylor K, Targan SR, Fleshner PR. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Diseases of the Colon & Rectum 1999;42:601-5. [DOI: 10.1007/bf02234133] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Nakai M, Sudo K, Yamada Y, Kojima Y, Kato T, Saito K, Moriwaki H, Seishima M. The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig Dis Sci 2005;50:1669-76. [PMID: 16133967 DOI: 10.1007/s10620-005-2913-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
54 Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32:384-393. [PMID: 20491747 DOI: 10.1111/j.1365-2036.2010.04360.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
55 Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181. [PMID: 8403503 DOI: 10.1111/j.1365-2249.1993.tb05997.x] [Cited by in Crossref: 570] [Cited by in F6Publishing: 588] [Article Influence: 19.7] [Reference Citation Analysis]
56 Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. [PMID: 12738464 DOI: 10.1111/j.1572-0241.2003.07343.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 116] [Article Influence: 7.0] [Reference Citation Analysis]
57 Gionchetti P, Campieri M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Poggioli G, Miglioli M, Barbara L. Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci 1994;39:1525-31. [PMID: 8026266 DOI: 10.1007/BF02088059] [Cited by in Crossref: 52] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
58 Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4. [PMID: 9176073 DOI: 10.1136/gut.40.4.470] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 2.4] [Reference Citation Analysis]
59 Heatley RV. Nutritional replenishment as an alternative to TNF-alpha in Crohn's disease. Lancet 1997;349:1702. [PMID: 9186412 DOI: 10.1016/s0140-6736(05)62678-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
60 Vasilyeva E, Abdulkhakov S, Cherepnev G, Martynova E, Mayanskaya I, Valeeva A, Abdulkhakov R, Safina D, Khaiboullina S, Rizvanov A. Serum Cytokine Profiles in Children with Crohn's Disease. Mediators Inflamm 2016;2016:7420127. [PMID: 28070144 DOI: 10.1155/2016/7420127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Ramadass SK, Jabaris SL, Perumal RK, Hairulislam VI, Gopinath A, Madhan B. Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy. European Journal of Pharmaceutical Sciences 2016;91:216-24. [DOI: 10.1016/j.ejps.2016.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
62 Zandee SEJ, O'connor RA, Mair I, Leech MD, Williams A, Anderton SM. IL‐10‐producing, ST2‐expressing Foxp3 + T cells in multiple sclerosis brain lesions. Immunol Cell Biol 2017;95:484-90. [DOI: 10.1038/icb.2017.3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
63 Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003;48:805-821; quiz 822-824. [PMID: 12789169 DOI: 10.1067/mjd.2003.540] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 7.8] [Reference Citation Analysis]
64 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
65 Pooley N, Ghosh L, Sharon P. Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Digest Dis Sci 1995;40:219-25. [DOI: 10.1007/bf02063969] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
66 Chowers Y, Lider O, Schor H, Barshack I, Tal R, Ariel A, Bar-Meir S, Cohen IR, Cahalon L. Disaccharides derived from heparin or heparan sulfate regulate IL-8 and IL-1 beta secretion by intestinal epithelial cells. Gastroenterology. 2001;120:449-459. [PMID: 11159885 DOI: 10.1053/gast.2001.21202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
67 Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995;108:1434-1444. [PMID: 7729636 DOI: 10.1016/0016-5085(95)90692-4] [Cited by in Crossref: 234] [Cited by in F6Publishing: 251] [Article Influence: 8.7] [Reference Citation Analysis]
68 Tarlton JF, Whiting CV, Tunmore D, Bregenholt S, Reimann J, Claesson MH, Bland PW. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol. 2000;157:1927-1935. [PMID: 11106565 DOI: 10.1016/s0002-9440(10)64831-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
69 Braegger CP. Immunopathogenesis of chronic inflammatory bowel disease. Acta Paediatr Suppl 1994;83:18-21. [PMID: 8025353 DOI: 10.1111/j.1651-2227.1994.tb13223.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
70 Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011;4:375-89. [PMID: 22043230 DOI: 10.1177/1756283X11413315] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
71 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660. [PMID: 21407183 DOI: 10.1038/ajg.2011.73] [Cited by in Crossref: 374] [Cited by in F6Publishing: 353] [Article Influence: 34.0] [Reference Citation Analysis]
72 Liu ZX, Hiwatashi N, Noguchi M, Toyota T. Increased expression of costimulatory molecules on peripheral blood monocytes in patients with Crohn's disease. Scand J Gastroenterol. 1997;32:1241-1246. [PMID: 9438323 DOI: 10.3109/00365529709028154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
73 Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43. [PMID: 12077089 DOI: 10.1136/gut.51.1.37] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 6.6] [Reference Citation Analysis]
74 Macdonald TT, Murch SH, Nicholls SW, Breese EJ. Intestinal cytokines in inflammatory bowel disease and invasive diarrhoea. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87:23-6. [DOI: 10.1016/0035-9203(93)90532-u] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Capaldo CT, Beeman N, Hilgarth RS, Nava P, Louis NA, Naschberger E, Stürzl M, Parkos CA, Nusrat A. IFN-γ and TNF-α-induced GBP-1 inhibits epithelial cell proliferation through suppression of β-catenin/TCF signaling. Mucosal Immunol 2012;5:681-90. [PMID: 22692453 DOI: 10.1038/mi.2012.41] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
76 Wang Y, Reen DJ, Puri P. Is a histologically normal appendix following emergency appendicectomy alway normal? Lancet 1996;347:1076-9. [PMID: 8602058 DOI: 10.1016/s0140-6736(96)90279-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
77 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
78 Ternant D, Le Tilly O, Picon L, Moussata D, Passot C, Bejan-Angoulvant T, Desvignes C, Mulleman D, Goupille P, Paintaud G. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. Pharmaceutics 2021;13:1821. [PMID: 34834236 DOI: 10.3390/pharmaceutics13111821] [Reference Citation Analysis]
79 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
80 Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T, Yoshida N, Minami M, Kita M, Imanishi J, Yoshikawa T. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003;18:560-9. [PMID: 12702049 DOI: 10.1046/j.1440-1746.2003.03034.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 5.5] [Reference Citation Analysis]
81 Pak S, Holland N, Garnett EA, Mileti E, Mahadevan U, Beckert R, Kanwar B, Heyman MB. Cytokine profiles in peripheral blood of children and adults with Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:769-75. [PMID: 22167015 DOI: 10.1097/MPG.0b013e3182455bb3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
82 Halpern MD, Clark JA, Saunders TA, Doelle SM, Hosseini DM, Stagner AM, Dvorak B. Reduction of experimental necrotizing enterocolitis with anti-TNF-alpha. Am J Physiol Gastrointest Liver Physiol. 2006;290:G757-G764. [PMID: 16269520 DOI: 10.1152/ajpgi.00408.2005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
83 Ménard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010;3:247-59. [PMID: 20404811 DOI: 10.1038/mi.2010.5] [Cited by in Crossref: 203] [Cited by in F6Publishing: 186] [Article Influence: 16.9] [Reference Citation Analysis]
84 Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Dig Dis Sci. 2004;49:1458-1460. [PMID: 15481319 DOI: 10.1023/b:ddas.0000042246.58984.98] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
85 Marafini I, Monteleone I, Dinallo V, Di Fusco D, De Simone V, Laudisi F, Fantini MC, Di Sabatino A, Pallone F, Monteleone G. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide. J Crohns Colitis 2017;11:603-9. [PMID: 28453765 DOI: 10.1093/ecco-jcc/jjw191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
86 Hamers AA, van Dam L, Teixeira Duarte JM, Vos M, Marinković G, van Tiel CM, Meijer SL, van Stalborch AM, Huveneers S, Te Velde AA, de Jonge WJ, de Vries CJ. Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFκB Activity in Macrophages. PLoS One 2015;10:e0133598. [PMID: 26241646 DOI: 10.1371/journal.pone.0133598] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
87 Zhang J, Lu Y, Wei J, Li L, Han L. Protective effect of carboxytmethylpachymaran on TNF-α-induced damage in Caco-2 cell monolayers. International Journal of Biological Macromolecules 2016;93:506-11. [DOI: 10.1016/j.ijbiomac.2016.07.095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
88 McNamee EN, Masterson JC, Veny M, Collins CB, Jedlicka P, Byrne FR, Ng GY, Rivera-Nieves J. Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis. J Leukoc Biol. 2015;97:1011-1022. [PMID: 25637591 DOI: 10.1189/jlb.3hi0614-303r] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
89 Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. The management of refractory Crohn's disease: REVIEW: MANAGEMENT OF REFRACTORY CROHN'S DISEASE. Alimentary Pharmacology & Therapeutics 2002;16:40-7. [DOI: 10.1046/j.1365-2036.16.s4.6.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
90 Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913-917. [PMID: 1885073 DOI: 10.1136/gut.32.8.913] [Cited by in Crossref: 338] [Cited by in F6Publishing: 334] [Article Influence: 10.9] [Reference Citation Analysis]
91 Shin B, Kress RL, Kramer PA, Darley-Usmar VM, Bellis SL, Harrington LE. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation. J Exp Med 2018;215:1803-12. [PMID: 29915024 DOI: 10.1084/jem.20172335] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
92 Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, Duclos B. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996;16:144-150. [PMID: 8734357 DOI: 10.1007/bf01540912] [Cited by in Crossref: 186] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
93 McCann TM, Ridyard AE, Else RW, Simpson JW. Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease. J Small Anim Pract 2007;48:620-5. [PMID: 17608662 DOI: 10.1111/j.1748-5827.2007.00335.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
94 Kontakou M, Przemioslo RT, Sturgess RP, Limb GA, Ellis HJ, Day P, Ciclitira PJ. Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge. Gut 1995;37:52-7. [PMID: 7672681 DOI: 10.1136/gut.37.1.52] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 2.0] [Reference Citation Analysis]
95 Dieleman LA, Beagley KW, Elson CO. The effect of immunosuppressive agents on monocyte generation and cytokine expression. Inflamm Bowel Dis 1995;1:266-75. [PMID: 23282425 DOI: 10.1097/00054725-199512000-00004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
96 Chowdhury M, Kudara N, Chiba T, Endo M, Akasaka R, Tomita K, Fujiwara S, Mizutani T, Sugai T, Takikawa Y, Suzuki K. Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy. Case Rep Gastroenterol 2009;3:193-7. [PMID: 21103274 DOI: 10.1159/000224712] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Damin DC, Santos FS, Heck R, Rosito MA, Meurer L, Kliemann LM, Roesler R, Schwartsmann G. Effects of the gastrin-releasing peptide antagonist RC-3095 in a rat model of ulcerative colitis. Dig Dis Sci 2010;55:2203-10. [PMID: 19894117 DOI: 10.1007/s10620-009-1032-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
98 Rook G, Thompson S, Buckley M, Elson C, Brealey R, Lambert C, White T, Rademacher T. The role of oil and agalactosyl IgG in the induction of arthritis in rodent models. Eur J Immunol 1991;21:1027-32. [DOI: 10.1002/eji.1830210425] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 1.5] [Reference Citation Analysis]
99 Mowat AM. Intestinal graft-versus-host disease. In: Macdonald TT, editor. Immunology of Gastrointestinal Disease. Dordrecht: Springer Netherlands; 1992. pp. 105-36. [DOI: 10.1007/978-94-011-2978-7_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
100 Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553-562. [PMID: 7600284 DOI: 10.1016/1074-7613(94)90045-0] [Cited by in Crossref: 831] [Cited by in F6Publishing: 795] [Article Influence: 30.8] [Reference Citation Analysis]
101 Burgos-Vargas R. Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis 2002;61 Suppl 3:iii33-9. [PMID: 12381509 DOI: 10.1136/ard.61.suppl_3.iii33] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
102 Principi M, Day R, Marangi S, Burattini O, De Francesco V, Ingrosso M, Pisani A, Panella C, Forbes A, Di Leo A, Francavilla A, Ierardi E. Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn’s Disease. Immunopharmacology and Immunotoxicology 2015;28:185-95. [DOI: 10.1080/08923970600815048a] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
103 Kontakou M, Przemioslo RT, Sturgess RP, Limb AG, Ciclitira PJ. Expression of Tumour Necrosis Factor-α, Interleukin-6, and Interleukin-2 mRNA in the Jejunum of Patients with Coeliac Disease. Scandinavian Journal of Gastroenterology 2009;30:456-63. [DOI: 10.3109/00365529509093307] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
104 Nair RP, Stuart P, Ogura Y, Inohara N, Chia NV, Young L, Henseler T, Jenisch S, Christophers E, Voorhees JJ, Nuñez G, Elder JT. Lack of Association Between NOD2 3020InsC Frameshift Mutation and Psoriasis. Journal of Investigative Dermatology 2001;117:1671-2. [DOI: 10.1046/j.0022-202x.2001.01620.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
105 Singh DP, Borse SP, Nivsarkar M. Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Transl Res 2016;175:76-91. [PMID: 27083387 DOI: 10.1016/j.trsl.2016.03.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
106 Bhatti S, Jaafar I, Hassan H, Atassi H, Stocker A, Hughes M, Pinkston C, Dryden G, Abell T. Effects of Gastric Neuromodulation on Crohn's Disease in Patients With Coexisting Symptoms of Gastroparesis. Neuromodulation: Technology at the Neural Interface 2020;23:1196-200. [DOI: 10.1111/ner.13118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709. [PMID: 8031350 DOI: 10.1136/gut.34.12.1705] [Cited by in Crossref: 345] [Cited by in F6Publishing: 340] [Article Influence: 12.3] [Reference Citation Analysis]
108 Moran GW, Thapaliya G. The Gut-Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation. Nutrients 2021;13:981. [PMID: 33803651 DOI: 10.3390/nu13030981] [Reference Citation Analysis]
109 Vong L, Ferraz JG, Panaccione R, Beck PL, Wallace JL. A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci USA. 2010;107:12023-12027. [PMID: 20547854 DOI: 10.1073/pnas.1004982107] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
110 Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut. 2001;48:326-332. [PMID: 11171821 DOI: 10.1136/gut.48.3.326] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 3.7] [Reference Citation Analysis]
111 Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45:856-863. [PMID: 10562584 DOI: 10.1136/gut.45.6.856] [Cited by in Crossref: 151] [Cited by in F6Publishing: 149] [Article Influence: 6.9] [Reference Citation Analysis]
112 Simpson SJ, Mizoguchi E, Allen D, Bhan AK, Terhorst C. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol. 1995;25:2618-2625. [PMID: 7589135 DOI: 10.1002/eji.1830250932] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 3.5] [Reference Citation Analysis]
113 Lee HB, Kim JH, Yim CY, Kim DG, Ahn DS. Differences in immunophenotyping of mucosal lymphocytes between ulcerative colitis and Crohn's disease. Korean J Intern Med. 1997;12:7-15. [PMID: 9159031 DOI: 10.3904/kjim.1997.12.1.7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
114 Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Association of TNF-alpha polymorphisms in Crohn disease. Hum Immunol. 2005;66:56-59. [PMID: 15620462 DOI: 10.1016/j.humimm.2004.10.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
115 Schreiber S. Activation of nuclear factor kappaB as a target for anti-inflammatory therapy. Gut 1999;44:309-10. [PMID: 10026311 DOI: 10.1136/gut.44.3.309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
116 Pooley N, Ghosh L, Blanchard J, Sharon P. Endothelial proliferation in experimental granulomatous colitis: Autoradiography and immunohistochemistry studies. Digest Dis Sci 1994;39:1197-209. [DOI: 10.1007/bf02093784] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
117 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
118 Miranda S, Roux ME. Acoustic stress induces long term severe intestinal inflammation in the mouse. Toxicol Lett 2017;280:1-9. [PMID: 28774831 DOI: 10.1016/j.toxlet.2017.07.898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
119 Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2820-2828. [PMID: 12425554 DOI: 10.1111/j.1572-0241.2002.07029.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 4.2] [Reference Citation Analysis]
120 Günzel D, Florian P, Richter JF, Troeger H, Schulzke JD, Fromm M, Gitter AH. Restitution of single-cell defects in the mouse colon epithelium differs from that of cultured cells. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1496-R1507. [PMID: 16397094 DOI: 10.1152/ajpregu.00470.2005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
121 Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology. 2002;122:2011-2025. [PMID: 12055606 DOI: 10.1053/gast.2002.33631] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 8.4] [Reference Citation Analysis]
122 al-Dawoud A, Nakshabendi I, Foulis A, Mowat AM. Immunohistochemical analysis of mucosal gamma-interferon production in coeliac disease. Gut 1992;33:1482-6. [PMID: 1452072 DOI: 10.1136/gut.33.11.1482] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 0.6] [Reference Citation Analysis]
123 Gulwani-akolkar B, Akolkar PN, Minassian A, Mckinley M, Fisher S, Silver J. CD4+ Cell Oligoclonality in Crohn's Disease: Evidence for an Antigen-Specific Response. Human Immunology 1996;48:114-24. [DOI: 10.1016/0198-8859(96)00079-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
124 Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn‘s disease: an open-label trial. Gastroenterology. 1999;117:1271-1277. [PMID: 10579967 DOI: 10.1016/s0016-5085(99)70276-3] [Cited by in Crossref: 227] [Cited by in F6Publishing: 37] [Article Influence: 9.9] [Reference Citation Analysis]
125 Pathmakanthan S, Li CK, Cowie J, Hawkey CJ. Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004;19:166-73. [DOI: 10.1111/j.1440-1746.2004.03181.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
126 Barikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J, Schramm C, Tiegs G, Sass G. Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice. Hepatology 2012;55:553-62. [PMID: 21953613 DOI: 10.1002/hep.24711] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
127 Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016; 22(42): 9300-9313 [PMID: 27895418 DOI: 10.3748/wjg.v22.i42.9300] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 83] [Article Influence: 15.2] [Reference Citation Analysis]
128 Berg DJ, Davidson N, Kühn R, Müller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20. [PMID: 8770874 DOI: 10.1172/JCI118861] [Cited by in Crossref: 823] [Cited by in F6Publishing: 373] [Article Influence: 31.7] [Reference Citation Analysis]
129 Macdermott RP. Alterations in the mucosal immune system in ulcerative colitis and crohn's disease. Medical Clinics of North America 1994;78:1207-31. [DOI: 10.1016/s0025-7125(16)30096-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
130 Das P, Goswami P, Das TK, Nag T, Sreenivas V, Ahuja V, Panda SK, Gupta SD, Makharia GK. Comparative tight junction protein expressions in colonic Crohn’s disease, ulcerative colitis, and tuberculosis: a new perspective. Virchows Arch 2012;460:261-70. [DOI: 10.1007/s00428-012-1195-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 5.4] [Reference Citation Analysis]
131 Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993;7:369-383. [PMID: 8105984 DOI: 10.1111/j.1365-2036.1993.tb00110.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 3.2] [Reference Citation Analysis]
132 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
133 van Deventer S. New biological therapies in inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 2003;17:119-30. [DOI: 10.1053/bega.2003.0360] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
134 Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A, Marconi M, Valli M, Novara F, Bonetti F. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn’s disease. Cytotherapy. 2009;11:825-836. [PMID: 19903096 DOI: 10.3109/14653240903121260] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
135 Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, Schreiber S. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-9. [DOI: 10.1053/gast.2003.50157] [Cited by in Crossref: 294] [Cited by in F6Publishing: 286] [Article Influence: 15.5] [Reference Citation Analysis]
136 Ghiassian SD, Voitalov I, Withers JB, Santolini M, Saleh A, Akmaev VR. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.03.006] [Reference Citation Analysis]
137 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133. [PMID: 10338381 DOI: 10.1097/00054725-199905000-00008] [Cited by in Crossref: 267] [Cited by in F6Publishing: 246] [Article Influence: 11.6] [Reference Citation Analysis]
138 Leucht K, Fischbeck A, Caj M, Liebisch G, Hartlieb E, Benes P, Fried M, Humpf HU, Rogler G, Hausmann M. Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells. Mol Nutr Food Res 2014;58:782-98. [PMID: 24142587 DOI: 10.1002/mnfr.201300369] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
139 Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kühbacher T, Hämling J, Fölsch UR, Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut. 2002;51:379-385. [PMID: 12171960 DOI: 10.1136/gut.51.3.379] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 6.8] [Reference Citation Analysis]
140 Bentz S, Pesch T, Wolfram L, de Vallière C, Leucht K, Fried M, Coy JF, Hausmann M, Rogler G. Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis. Am J Physiol Gastrointest Liver Physiol 2011;300:G598-607. [PMID: 21233279 DOI: 10.1152/ajpgi.00323.2010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
141 Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T, Ohsuga M, Kyokane K, Sakai T, Nishio Y. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease. J Gastroenterol Hepatol. 1999;14:46-53. [PMID: 10029277 DOI: 10.1046/j.1440-1746.1999.01807.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 2.5] [Reference Citation Analysis]
142 Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542-553. [PMID: 15224278 DOI: 10.1016/s1542-3565(04)00238-1] [Cited by in Crossref: 429] [Cited by in F6Publishing: 98] [Article Influence: 23.8] [Reference Citation Analysis]
143 Walrath T, Malizia RA, Zhu X, Sharp SP, D'Souza SS, Lopez-Soler R, Parr B, Kartchner B, Lee EC, Stain SC, Iwakura Y, O'Connor W Jr. IFN-γ and IL-17A regulate intestinal crypt production of CXCL10 in the healthy and inflamed colon. Am J Physiol Gastrointest Liver Physiol 2020;318:G479-89. [PMID: 31790273 DOI: 10.1152/ajpgi.00208.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
144 Abdelshaheed NN, Goldberg DM. Biochemical tests in diseases of the intestinal tract: their contributions to diagnosis, management, and understanding the pathophysiology of specific disease states. Crit Rev Clin Lab Sci 1997;34:141-223. [PMID: 9143817 DOI: 10.3109/10408369709049587] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
145 Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582. [PMID: 20234346 DOI: 10.1038/ajg.2010.78] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 12.5] [Reference Citation Analysis]
146 Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 2011;59:161-177. [PMID: 21445715 DOI: 10.1007/s00005-011-0122-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
147 Prieto-Vicente V, Sánchez-Garrido AI, Blanco-Gozalo V, Arévalo M, García-Sánchez E, López-Montañés D, Quiros Y, López-Hernández FJ, Rodríguez-Pérez A, López-Novoa JM. Cardiotrophin-1 attenuates experimental colitis in mice. Clin Sci (Lond) 2018;132:985-1001. [PMID: 29572384 DOI: 10.1042/CS20171513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Roda G, Sartini A, Zambon E, Calafiore A, Marocchi M, Caponi A, Belluzzi A, Roda E. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol 2010; 16(34): 4264-4271 [PMID: 20818809 DOI: 10.3748/wjg.v16.i34.4264] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 72] [Article Influence: 6.4] [Reference Citation Analysis]
149 Gutiérrez-Martínez IZ, Rubio JF, Piedra-Quintero ZL, Lopez-Mendez O, Serrano C, Reyes-Maldonado E, Salinas-Lara C, Betanzos A, Shibayama M, Silva-Olivares A, Candelario-Martinez A, Meraz-Ríos MA, Schnoor M, Villegas-Sepúlveda N, Nava P. mTORC1 Prevents Epithelial Damage During Inflammation and Inhibits Colitis-Associated Colorectal Cancer Development. Transl Oncol 2019;12:24-35. [PMID: 30265974 DOI: 10.1016/j.tranon.2018.08.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
150 Rückert Y, Schindler U, Heinig T, Nikolaus S, Raedler A, Schreiber S. IL-4 Signaling Mechanisms in Inflammatory Bowel Disease Mononuclear Phagocytes: . Inflammatory Bowel Diseases 1996;2:244-52. [DOI: 10.1097/00054725-199612000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
151 Brosbøl-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, Rosenstiel P, Höllsberg P. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin Exp Immunol 2009;155:487-95. [PMID: 19094116 DOI: 10.1111/j.1365-2249.2008.03850.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
152 Coskun M, Troelsen JT, Nielsen OH. The role of CDX2 in intestinal homeostasis and inflammation. Biochim Biophys Acta. 2011;1812:283-289. [PMID: 21126581 DOI: 10.1016/j.bbadis.2010.11.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
153 Peña AS, Crusius JB. Food allergy, coeliac disease and chronic inflammatory bowel disease in man. Vet Q 1998;20 Suppl 3:S49-52. [PMID: 9689726 [PMID: 9689726 DOI: 10.1080/01652176.1998.9694969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
154 Schreiber S, Hämling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6. [PMID: 9245930 DOI: 10.1136/gut.40.6.761] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 2.6] [Reference Citation Analysis]
155 Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350. [PMID: 9100984 DOI: 10.1016/s0065-2776(08)60891-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
156 Gustafson-Svärd C, Lilja I, Sjödahl R, Tagesson C. Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407). Scand J Gastroenterol 1995;30:1000-7. [PMID: 8545605 DOI: 10.3109/00365529509096345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
157 Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH, Dixon MF, Axon AT. Adhesion molecules in inflammatory bowel disease. Gut 1995;36:724-30. [PMID: 7541009 DOI: 10.1136/gut.36.5.724] [Cited by in Crossref: 131] [Cited by in F6Publishing: 126] [Article Influence: 4.9] [Reference Citation Analysis]
158 Pearl DS, Shah K, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK, Trebble TM. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohns Colitis. 2013;7:481-489. [PMID: 22974822 DOI: 10.1016/j.crohns.2012.07.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
159 Rintamäki H, Sipponen T, Salo HM, Vaarala O, Kolho KL. Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease. World J Gastroenterol 2010; 16(46): 5845-5851 [PMID: 21155006 DOI: 10.3748/wjg.v16.i46.5845] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Halpern MD, Holubec H, Dominguez JA, Meza YG, Williams CS, Ruth MC, McCuskey RS, Dvorak B. Hepatic inflammatory mediators contribute to intestinal damage in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2003;284:G695-702. [PMID: 12529262 DOI: 10.1152/ajpgi.00353.2002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]
161 D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-1034. [PMID: 10220494 DOI: 10.1016/s0016-5085(99)70005-3] [Cited by in Crossref: 502] [Cited by in F6Publishing: 137] [Article Influence: 21.8] [Reference Citation Analysis]
162 Jarry A, Muzeau F, Laboisse C. Cytokine effects in a human colonic goblet cell line: Cellular damage and its partial prevention by 5 aminosalicylic acid. Digest Dis Sci 1992;37:1170-8. [DOI: 10.1007/bf01296556] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
163 Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
164 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Reference Citation Analysis]
165 Hartman DS, Tracey DE, Lemos BR, Erlich EC, Burton RE, Keane DM, Patel R, Kim S, Bhol KC, Harris MS. Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis. J Crohns Colitis. 2016;10:641-649. [PMID: 26802087 DOI: 10.1093/ecco-jcc/jjw026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
166 Ginsburg PM, Hanan I, Ehrenpreis ED. Treatment of Severe Esophageal Crohnʼs Disease With Thalidomide: . American Journal of Gastroenterology 2001;96:1305-6. [DOI: 10.1111/j.1572-0241.2001.03729.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
167 Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577-5585. [PMID: 20921534 DOI: 10.4049/jimmunol.1000548] [Cited by in Crossref: 240] [Cited by in F6Publishing: 234] [Article Influence: 20.0] [Reference Citation Analysis]
168 Schreiber S, Raedler A, Stenson WF, Macdermott RP. THE ROLE OF THE MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL DISEASE. Gastroenterology Clinics of North America 1992;21:451-502. [DOI: 10.1016/s0889-8553(21)00040-6] [Cited by in Crossref: 49] [Article Influence: 1.6] [Reference Citation Analysis]
169 Williams AM, Whiting CV, Bonhagen K, Reimann J, Bregenholt S, Claesson MH, Bland PW. Tumour necrosis factor-alpha (TNF-alpha) transcription and translation in the CD4+ T cell-transplanted scid mouse model of colitis. Clin Exp Immunol 1999;116:415-24. [PMID: 10361228 DOI: 10.1046/j.1365-2249.1999.00915.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
170 Walker WA. Uptake of antigens: Role in gastrointestinal disease. Pediatrics International 1994;36:597-610. [DOI: 10.1111/j.1442-200x.1994.tb03252.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Bauer C, Loher F, Dauer M, Mayer C, Lehr HA, Schönharting M, Hallwachs R, Endres S, Eigler A. The ICE Inhibitor Pralnacasan Prevents DSS-Induced Colitis in C57BL/6 Mice and Suppresses IP-10 mRNA but Not TNF-α mRNA Expression. Dig Dis Sci 2007;52:1642-52. [DOI: 10.1007/s10620-007-9802-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
172 Plevy S. Do Serological Markers and Cytokines Determine the Indeterminate? Journal of Clinical Gastroenterology 2004;38:S51-6. [DOI: 10.1097/01.mcg.0000124026.92823.fc] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
173 He J, Brimmo AT, Qasaimeh MA, Chen P, Chen W. Recent Advances and Perspectives in Microfluidics-Based Single-Cell Biosensing Techniques. Small Methods 2017;1:1700192. [DOI: 10.1002/smtd.201700192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
174 Monteleone I, Marafini I, Dinallo V, Di Fusco D, Troncone E, Zorzi F, Laudisi F, Monteleone G. Sodium chloride-enriched Diet Enhanced Inflammatory Cytokine Production and Exacerbated Experimental Colitis in Mice. J Crohns Colitis. 2017;11:237-245. [PMID: 27473029 DOI: 10.1093/ecco-jcc/jjw139] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
175 Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61 Suppl 3:iii51-60. [PMID: 12381511 DOI: 10.1136/ard.61.suppl_3.iii51] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
176 Choi SJ, Kim MS, Kim ES, Lee J, Lee JM, Choi HS, Keum B, Jeen YT, Lee HS, Chun HJ, Kim CD. Higher risk of tuberculosis in combination therapy for inflammatory bowel disease: A nationwide population-based cohort study in South Korea. Medicine (Baltimore) 2020;99:e22897. [PMID: 33126343 DOI: 10.1097/MD.0000000000022897] [Reference Citation Analysis]
177 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
178 Mueller PE, Eades SC, Moore JN, Barton MH. Contribution of tumor necrosis factor alpha to endotoxin-induced mucosal dysfunction in the feline jejunum. Journal of Endotoxin Research 1996;3:323-32. [DOI: 10.1177/096805199600300406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Macdermoit RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996;31:907-16. [DOI: 10.1007/bf02358624] [Cited by in Crossref: 89] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
180 Saito Y, Shimizu M, Iwatsuki K, Hanyu H, Tadaishi M, Sugita-Konishi Y, Kobayashi-Hattori K. Effect of short-time treatment with TNF-α on stem cell activity and barrier function in enteroids. Cytotechnology 2021;73:669-82. [PMID: 34349355 DOI: 10.1007/s10616-021-00487-y] [Reference Citation Analysis]
181 Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn’s Disease. American Journal of Gastroenterology 2016;111:529-40. [DOI: 10.1038/ajg.2016.8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
182 Spagnuolo PA, Hoffman-goetz L. Dietary Lactoferrin Does Not Prevent Dextran Sulfate Sodium Induced Murine Intestinal Lymphocyte Death. Exp Biol Med (Maywood) 2008;233:1099-108. [DOI: 10.3181/0802-rm-53] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
183 Hendel J, Brynskov J, Særmark T, Bendtzen K. Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Expert Opinion on Investigational Drugs 2008;5:843-50. [DOI: 10.1517/13543784.5.7.843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Patterson AM, Delday MI, van Kuppevelt TH, Loh G, Blaut M, Haller D, Grant G, Kelly D. Expression of heparan sulfate proteoglycans in murine models of experimental colitis*: . Inflammatory Bowel Diseases 2012;18:1112-26. [DOI: 10.1002/ibd.21879] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
185 Hofmann C, Dunger N, Schölmerich J, Falk W, Obermeier F. Glycogen synthase kinase 3-β: a master regulator of toll-like receptor-mediated chronic intestinal inflammation. Inflamm Bowel Dis 2010;16:1850-8. [PMID: 20848477 DOI: 10.1002/ibd.21294] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
186 Owens MW, Grisham MB. Cytokines increase proliferation of human intestinal smooth muscle cells: possible role in inflammation-induced stricture formation. Inflammation 1993;17:481-7. [PMID: 8406690 DOI: 10.1007/BF00916587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
187 Baumgart DC, Olivier WA, Reya T, Peritt D, Rombeau JL, Carding SR. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell Immunol. 1998;187:52-66. [PMID: 9682004 DOI: 10.1006/cimm.1998.1307] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.2] [Reference Citation Analysis]
188 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1079-1093. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
189 Park S, Neupane GP, Lee SO, Lee JS, Kim M, Kim SY, Park BC, Park Y, Kim J. Protective effects of Pogostemon cablin Bentham water extract on inflammatory cytokine expression in TNBS-induced colitis in rats. Arch Pharm Res 2014;37:253-62. [DOI: 10.1007/s12272-013-0260-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
190 Horgan L, Mulrennan S, D'Orsogna L, McLean-Tooke A. Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature. BMC Gastroenterol. 2019;19:171. [PMID: 31675916 DOI: 10.1186/s12876-019-1091-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Schottelius A, Wedel S, Weltrich R, Rohde W, Buttgereit F, Schreiber S, Lochs H. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterology 2000;95:1994-9. [DOI: 10.1111/j.1572-0241.2000.02188.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
192 Digby-Bell JL, Atreya R, Monteleone G, Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:9-20. [PMID: 31767987 DOI: 10.1038/s41575-019-0228-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
193 Goettel JA, Scott Algood HM, Olivares-Villagómez D, Washington MK, Chaturvedi R, Wilson KT, Van Kaer L, Polk DB. KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production. Gastroenterology 2011;140:265-74. [PMID: 20875416 DOI: 10.1053/j.gastro.2010.09.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
194 Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464. [PMID: 16500392 DOI: 10.1016/j.gie.2005.08.011] [Cited by in Crossref: 394] [Cited by in F6Publishing: 344] [Article Influence: 24.6] [Reference Citation Analysis]
195 Coskun M, Olsen AK, Holm TL, Kvist PH, Nielsen OH, Riis LB, Olsen J, Troelsen JT. TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis. Biochim Biophys Acta. 2012;1822:843-851. [PMID: 22326557 DOI: 10.1016/j.bbadis.2012.01.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
196 Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Annals of Medicine 2009;33:516-25. [DOI: 10.3109/07853890108995961] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
197 Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases: . Inflammatory Bowel Diseases 2011;17:362-81. [DOI: 10.1002/ibd.21403] [Cited by in Crossref: 296] [Cited by in F6Publishing: 297] [Article Influence: 26.9] [Reference Citation Analysis]
198 Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology. 2008;47:888-896. [PMID: 18306229 DOI: 10.1002/hep.22125] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
199 Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol. 2011;5:703-716. [PMID: 22017698 DOI: 10.1586/egh.11.74] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
200 Comeche JM, Comino I, Altavilla C, Tuells J, Gutierrez-Hervas A, Caballero P. Parenteral Nutrition in Patients with Inflammatory Bowel Disease Systematic Review, Meta-Analysis and Meta-Regression. Nutrients 2019;11:E2865. [PMID: 31766687 DOI: 10.3390/nu11122865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
201 Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, Raedler A. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology. 1995;108:21-33. [PMID: 7806044 DOI: 10.1016/0016-5085(95)90004-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 2.7] [Reference Citation Analysis]
202 Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3-20; quiz 21-2. [PMID: 19560575 DOI: 10.1016/j.jaci.2009.05.038] [Cited by in Crossref: 794] [Cited by in F6Publishing: 748] [Article Influence: 61.1] [Reference Citation Analysis]
203 Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut. 1998;42:470-476. [PMID: 9616306 DOI: 10.1136/gut.42.4.470] [Cited by in Crossref: 157] [Cited by in F6Publishing: 157] [Article Influence: 6.5] [Reference Citation Analysis]
204 Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol 2001;96:2946-56. [PMID: 11693331 DOI: 10.1111/j.1572-0241.2001.04686.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 2.3] [Reference Citation Analysis]
205 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
206 Ruemmele FM, Seidman EG, Lentze MJ. Regulation of intestinal epithelial cell apoptosis and the pathogenesis of inflammatory bowel disorders. J Pediatr Gastroenterol Nutr. 2002;34:254-260. [PMID: 11964947 DOI: 10.1097/00005176-200203000-00005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
207 Bregenholt S, Claesson MH. Increased intracellular Th1 cytokines in scid mice with inflammatory bowel disease. Eur J Immunol 1998;28:379-89. [PMID: 9485217 DOI: 10.1002/(SICI)1521-4141(199801)28:01<379::AID-IMMU379>3.0.CO;2-X] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
208 Ishii N, Chiba M, Iizuka M, Horie Y, Masamune O. Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-alpha and interferon-gamma. Scand J Gastroenterol 1994;29:903-7. [PMID: 7530858 DOI: 10.3109/00365529409094861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
209 Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110-119. [PMID: 26808166 DOI: 10.1016/j.pharmthera.2016.01.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
210 Yau Y, Leong RW, Zeng M, Wasinger VC. Proteomics and metabolomics in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1076-1086. [PMID: 23489082 DOI: 10.1111/jgh.12193] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
211 Ghiassian SD, Withers JB, Santolini M, Saleh A, Akmaev VR. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Transl Res 2021:S1931-5244(21)00106-7. [PMID: 33965585 DOI: 10.1016/j.trsl.2021.04.010] [Reference Citation Analysis]
212 Capobianchi MR, Fais S, Mercuri F, Boirivant M, Dianzani F, Pallone F. Interferon-alpha (IFN-alpha) production by human intestinal mononuclear cells. Response to virus in control subjects and in Crohn's disease. Gut 1992;33:897-901. [PMID: 1644329 DOI: 10.1136/gut.33.7.897] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
213 Zachariassen LF, Hansen AK, Krych L, Nielsen DS, Holm TL, Tougaard P, Hansen CHF. Cesarean section increases sensitivity to oxazolone-induced colitis in C57BL/6 mice. Mucosal Immunol 2019;12:1348-57. [DOI: 10.1038/s41385-019-0207-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
214 Hayashi M, Martinez OM, Krams SM, Burns W, Esquivel CO. Characterization of allograft rejection in an experimental model of small intestinal transplantation. J Gastrointest Surg 1998;2:325-32. [PMID: 9841989 DOI: 10.1016/s1091-255x(98)80071-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
215 Davidson NJ, Fort MM, Müller W, Leach MW, Rennick DM. Chronic colitis in IL-10-/- mice: insufficient counter regulation of a Th1 response. Int Rev Immunol. 2000;19:91-121. [PMID: 10723680 DOI: 10.3109/08830180009048392] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 2.7] [Reference Citation Analysis]
216 Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761-769. [PMID: 10500056 DOI: 10.1016/s0016-5085(99)70332-x] [Cited by in Crossref: 750] [Cited by in F6Publishing: 137] [Article Influence: 32.6] [Reference Citation Analysis]
217 Yakymenko O, Schoultz I, Gullberg E, Ström M, Almer S, Wallon C, Wang A, Keita ÅV, Campbell BJ, McKay DM, Söderholm JD. Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn's disease via effects on epithelial lipid rafts. Scand J Gastroenterol 2018;53:677-84. [PMID: 29688802 DOI: 10.1080/00365521.2018.1458146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
218 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
219 Kontakou M, Sturgess RP, Przemioslo RT, Limb GA, Nelufer JM, Ciclitira PJ. Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation. Gut 1994;35:1037-41. [PMID: 7926902 DOI: 10.1136/gut.35.8.1037] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 1.6] [Reference Citation Analysis]
220 Ingram JR, Rhodes J, Evans BK, Thomas GA. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol Res Pract 2008;2008:237185. [PMID: 18795117 DOI: 10.1155/2008/237185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
221 Wall GC, Heyneman C, Pfanner TP. Medical Options for Treating Crohn’s Disease in Adults: Focus on Antitumor Necrosis Factor-α Chimeric Monoclonal Antibody. Pharmacotherapy 1999;19:1138-52. [DOI: 10.1592/phco.19.15.1138.30574] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
222 Qasem A, Ramesh S, Naser SA. Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn's disease. BMJ Open Gastroenterol 2019;6:e000246. [PMID: 30815272 DOI: 10.1136/bmjgast-2018-000246] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
223 Nikolaus S, Waetzig GH, Butzin S, Ziolkiewicz M, Al-Massad N, Thieme F, Lövgren U, Rasmussen BB, Reinheimer TM, Seegert D, Rosenstiel P, Szymczak S, Schreiber S. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases. Int J Colorectal Dis 2018;33:927-36. [PMID: 29748708 DOI: 10.1007/s00384-018-3069-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
224 Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology. 1999;117:1278-1287. [PMID: 10579968 DOI: 10.1016/s0016-5085(99)70277-5] [Cited by in Crossref: 210] [Cited by in F6Publishing: 30] [Article Influence: 9.1] [Reference Citation Analysis]
225 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
226 Ruemmele FM, Beaulieu JF, Dionne S, Levy E, Seidman EG, Cerf-Bensussan N, Lentze MJ. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut 2002;51:842-8. [PMID: 12427787 DOI: 10.1136/gut.51.6.842] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 3.7] [Reference Citation Analysis]
227 Elsässer-Beile U, von Kleist S, Gerlach S, Gallati H, Mönting JS. Cytokine production in whole blood cell cultures of patients with Crohn's disease and ulcerative colitis. J Clin Lab Anal. 1994;8:447-451. [PMID: 7869186 DOI: 10.1002/jcla.1860080618] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
228 Steinhoff U, Brinkmann V, Klemm U, Aichele P, Seiler P, Brandt U, Bland PW, Prinz I, Zügel U, Kaufmann SH. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 1999;11:349-58. [PMID: 10514013 DOI: 10.1016/s1074-7613(00)80110-7] [Cited by in Crossref: 99] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
229 Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295-302. [PMID: 15306588 DOI: 10.1136/gut.2003.036632] [Cited by in Crossref: 213] [Cited by in F6Publishing: 215] [Article Influence: 11.8] [Reference Citation Analysis]
230 Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998;42:477-484. [PMID: 9616307 DOI: 10.1136/gut.42.4.477] [Cited by in Crossref: 498] [Cited by in F6Publishing: 505] [Article Influence: 20.8] [Reference Citation Analysis]
231 Hausmann M. How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation. Int J Inflam 2010;2010:574568. [PMID: 21188215 DOI: 10.4061/2010/574568] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
232 Oshima T, Laroux FS, Coe LL, Morise Z, Kawachi S, Bauer P, Grisham MB, Specian RD, Carter P, Jennings S. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res. 2001;61:130-143. [PMID: 11162203 DOI: 10.1006/mvre.2000.2288] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 5.7] [Reference Citation Analysis]
233 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
234 Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004;:CD003574. [PMID: 14974022 DOI: 10.1002/14651858.CD003574.pub2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 36] [Article Influence: 1.3] [Reference Citation Analysis]
235 Boyle EC, Finlay BB. Leaky guts and lipid rafts. Trends Microbiol 2005;13:560-3. [PMID: 16253506 DOI: 10.1016/j.tim.2005.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
236 Sales-Campos H, de Souza PR, Basso PJ, Ramos AD, Nardini V, Chica JE, Capurro ML, Sá-Nunes A, de Barros Cardoso CR. Aedes aegypti salivary gland extract ameliorates experimental inflammatory bowel disease. Int Immunopharmacol 2015;26:13-22. [PMID: 25770821 DOI: 10.1016/j.intimp.2015.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
237 Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer CJ, Brand S. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 2007;56:1257-65. [PMID: 17449633 DOI: 10.1136/gut.2006.118679] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 5.2] [Reference Citation Analysis]
238 Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008;48:988-1000. [PMID: 18346021 DOI: 10.1111/j.1537-2995.2007.01633.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.2] [Reference Citation Analysis]
239 Kudo T, Nagata S, Aoyagi Y, Suzuki R, Matsuda H, Ohtsuka Y, Shimizu T, Okumura K, Yamashiro Y. Polarized Production of T-Helper Cell Type 1 Cells in Peyer’s Patches in Crohn’s Disease. Digestion 2005;70:214-25. [DOI: 10.1159/000082892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
240 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
241 Caldwell AB, Cheng Z, Vargas JD, Birnbaum HA, Hoffmann A. Network dynamics determine the autocrine and paracrine signaling functions of TNF. Genes Dev 2014;28:2120-33. [PMID: 25274725 DOI: 10.1101/gad.244749.114] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
242 Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Digestion. 2017;95:188-193. [PMID: 28288458 DOI: 10.1159/000455008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
243 Khan MA. Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 2002;61 Suppl 3:iii3-7. [PMID: 12381505 DOI: 10.1136/ard.61.suppl_3.iii3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
244 Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146-53. [PMID: 14678276 DOI: 10.1111/j.1365-2249.2004.02348.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
245 Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141:2026-2038. [PMID: 21875498 DOI: 10.1053/j.gastro.2011.08.032] [Cited by in Crossref: 140] [Cited by in F6Publishing: 144] [Article Influence: 12.7] [Reference Citation Analysis]
246 Autschbach F, Braunstein J, Helmke B, Zuna I, Schürmann G, Niemir ZI, Wallich R, Otto HF, Meuer SC. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol. 1998;153:121-130. [PMID: 9665472 DOI: 10.1016/S0002-9440(10)65552-6] [Cited by in Crossref: 102] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
247 Crowe A, Taffinder N, Layer GT, Irvine A, Nicholls RJ. Portal vein thrombosis in a complicated case of Crohn's disease. Postgrad Med J. 1992;68:291-293. [PMID: 1409198 DOI: 10.1136/pgmj.68.798.291] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
248 Gasché C, Reinisch W, Vogelsang H, Pötzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995;40:800-4. [PMID: 7720472 DOI: 10.1007/BF02064982] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
249 Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 1999;116:557-565. [PMID: 10029614 DOI: 10.1016/s0016-5085(99)70177-0] [Cited by in Crossref: 178] [Cited by in F6Publishing: 56] [Article Influence: 7.7] [Reference Citation Analysis]
250 Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J, Gross V. Nuclear Factor κB Is Activated in Macrophages and Epithelial Cells of Inflamed Intestinal Mucosa. Gastroenterology. 1998;115:357-369. [PMID: 9679041 DOI: 10.1016/s0016-5085(98)70202-1] [Cited by in Crossref: 477] [Cited by in F6Publishing: 179] [Article Influence: 19.9] [Reference Citation Analysis]
251 Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 2010;45:266-276. [PMID: 20076977 DOI: 10.1007/s00535-009-0191-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
252 Gonçalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. Inflamm Bowel Dis 2015;21:453-67. [PMID: 25248003 DOI: 10.1097/MIB.0000000000000209] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 6.1] [Reference Citation Analysis]
253 Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, Silver J. Effects of Infliximab on Apoptosis and Reverse Signaling of Monocytes from Healthy Individuals and Patients with Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:801-10. [DOI: 10.1097/00054725-200411000-00015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
254 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
255 Ternant D, Pfister M, Le Tilly O, Mulleman D, Picon L, Willot S, Passot C, Bejan-Angoulvant T, Lecomte T, Paintaud G, Koch G. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. Clin Pharmacokinet 2021. [PMID: 34351609 DOI: 10.1007/s40262-021-01057-3] [Reference Citation Analysis]
256 Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481-1484. [PMID: 17429728 DOI: 10.1007/s10620-006-9250-x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 125] [Article Influence: 10.2] [Reference Citation Analysis]
257 Gross V, Andus T, Leser HG, Roth M, Schölmerich J. Inflammatory mediators in chronic inflammatory bowel diseases. Klin Wochenschr 1991;69:981-7. [PMID: 1798295 DOI: 10.1007/BF01645143] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
258 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
259 Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007;56:61-72. [PMID: 16822808 DOI: 10.1136/gut.2006.094375] [Cited by in Crossref: 716] [Cited by in F6Publishing: 705] [Article Influence: 44.8] [Reference Citation Analysis]
260 Adesso S, Autore G, Quaroni A, Popolo A, Severino L, Marzocco S. The Food Contaminants Nivalenol and Deoxynivalenol Induce Inflammation in Intestinal Epithelial Cells by Regulating Reactive Oxygen Species Release. Nutrients 2017;9:E1343. [PMID: 29232919 DOI: 10.3390/nu9121343] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
261 Sabui S, Kapadia R, Ghosal A, Schneider M, Lambrecht NWG, Said HM. Biotin and pantothenic acid oversupplementation to conditional SLC5A6 KO mice prevents the development of intestinal mucosal abnormalities and growth defects. Am J Physiol Cell Physiol 2018;315:C73-9. [PMID: 29669219 DOI: 10.1152/ajpcell.00319.2017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
262 Brandtzaeg P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997;18:555-89. [PMID: 9144870 DOI: 10.1007/BF00824058] [Cited by in Crossref: 56] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
263 Gotteland M, Lopez M, Muñoz C, Saez R, Altshiller H, Llorens P, Brunser O. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci. 1999;44:830-835. [PMID: 10219845 DOI: 10.1023/A: 1026690631693] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66. [PMID: 8194690 DOI: 10.1016/0016-5085(94)90398-0] [Cited by in Crossref: 410] [Cited by in F6Publishing: 391] [Article Influence: 14.6] [Reference Citation Analysis]
265 Ibbotson JP, Lowes JR. Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease. Gut 1995;36:1-4. [PMID: 7534251 DOI: 10.1136/gut.36.1.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
266 Fukushima K, West G, Fiocchi C. Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA: Comparative study of RT-PCR in biopsies and isolated cells from normal and inflamed intestine. Digest Dis Sci 1995;40:1498-505. [DOI: 10.1007/bf02285198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
267 Coutinho de Sousa B, Reis Machado J, da Silva MV, da Costa TA, Lazo-Chica JE, Degasperi TD, Rodrigues Junior V, Sales-Campos H, Uber Bucek E, Freire Oliveira CJ. Morinda citrifolia (Noni) Fruit Juice Reduces Inflammatory Cytokines Expression and Contributes to the Maintenance of Intestinal Mucosal Integrity in DSS Experimental Colitis. Mediators Inflamm. 2017;2017:6567432. [PMID: 28194046 DOI: 10.1155/2017/6567432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
268 Beagley KW, Elson CO. CELLS AND CYTOKINES IN MUCOSAL IMMUNITY AND INFLAMMATION. Gastroenterology Clinics of North America 1992;21:347-66. [DOI: 10.1016/s0889-8553(21)00035-2] [Cited by in Crossref: 39] [Article Influence: 1.3] [Reference Citation Analysis]
269 Isaacs KL, Sartor R, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95. [DOI: 10.1016/0016-5085(92)91182-4] [Cited by in Crossref: 224] [Cited by in F6Publishing: 234] [Article Influence: 7.5] [Reference Citation Analysis]
270 Vanhove W, Nys K, Vermeire S. Therapeutic innovations in inflammatory bowel diseases. Clin Pharmacol Ther. 2016;99:49-58. [PMID: 26509246 DOI: 10.1002/cpt.286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
271 Corazza N, Eichenberger S, Eugster HP, Mueller C. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 1999;190:1479-92. [PMID: 10562322 DOI: 10.1084/jem.190.10.1479] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 4.2] [Reference Citation Analysis]
272 Mahgoub A, El-medany A, Mustafa A, Arafah M, Moursi M. Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats. Toxicology and Applied Pharmacology 2005;205:43-52. [DOI: 10.1016/j.taap.2004.09.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
273 Siebert S, Tsoukas A, Robertson J, Mcinnes I, Touyz RM. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacol Rev 2015;67:280-309. [DOI: 10.1124/pr.114.009639] [Cited by in Crossref: 196] [Cited by in F6Publishing: 180] [Article Influence: 28.0] [Reference Citation Analysis]
274 Robijn RJ, Logtenberg T, Wiegman LJJM, Van Berge Henegouwen GP, Houwen RW, Koningsberger JC. Intestinal T Lymphocytes. Scandinavian Journal of Gastroenterology 2009;30:23-33. [DOI: 10.3109/00365529509090298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
275 Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond). 2010;118:707-715. [PMID: 20350293 DOI: 10.1042/cs20100027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
276 Salmenperä P, Hämäläinen S, Hukkanen M, Kankuri E. Interferon-γ induces C/EBPβ expression and activity through MEK/ERK and p38 in T84 colon epithelial cells. American Journal of Physiology-Cell Physiology 2003;284:C1133-9. [DOI: 10.1152/ajpcell.00293.2002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
277 Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease - A controlled clinical trial. Phytomedicine. 2010;17:305-309. [PMID: 19962291 DOI: 10.1016/j.phymed.2009.10.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
278 Aly E, López-Nicolás R, Darwish AA, Ros-Berruezo G, Frontela-Saseta C. In vitro effectiveness of recombinant human lactoferrin and its hydrolysate in alleviating LPS-induced inflammatory response. Food Res Int 2019;118:101-7. [PMID: 30898345 DOI: 10.1016/j.foodres.2017.12.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
279 Biancheri P, Powell N, Monteleone G, Lord G, MacDonald TT. The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol 2013;34:564-71. [PMID: 24035478 DOI: 10.1016/j.it.2013.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
280 Gardiner KR, Halliday MI, Lloyd F, Stephens S, Rowlands BJ. Circulating Tumour Necrosis Factor in Active Inflammatory Bowel Disease. In: Faist E, Meakins JL, Schildberg FW, editors. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin: Springer Berlin Heidelberg; 1993. pp. 699-703. [DOI: 10.1007/978-3-642-77405-8_90] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
281 León F, Sánchez L, Camarero C, Roy G. Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease. Dig Dis Sci. 2005;50:593-600. [PMID: 15810648 DOI: 10.1007/s10620-005-2480-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
282 Pallapies D, Peskar BA, Peskar BM. Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human platelets. European Journal of Pharmacology 1995;282:145-9. [DOI: 10.1016/0014-2999(95)00305-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
283 Ciancio MJ, Vitiritti L, Dhar A, Chang EB. Endotoxin-induced alterations in rat colonic water and electrolyte transport. Gastroenterology 1992;103:1437-43. [DOI: 10.1016/0016-5085(92)91162-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698. [PMID: 21427713 DOI: 10.1038/ajg.2011.103] [Cited by in Crossref: 202] [Cited by in F6Publishing: 198] [Article Influence: 18.4] [Reference Citation Analysis]
285 Gotteland M, Lopez M, Muñoz C, Saez R, Altshiller H, Llorens P, Brunser O. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci 1999;44:830-5. [PMID: 10219845 DOI: 10.1023/a:1026690631693] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
286 Zareie M, Mckay DM, Kovarik GG, Perdue MH. Monocyte/macrophages evoke epithelial dysfunction: indirect role of tumor necrosis factor-α. American Journal of Physiology-Cell Physiology 1998;275:C932-9. [DOI: 10.1152/ajpcell.1998.275.4.c932] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
287 Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol. 2004;138:323-329. [PMID: 15498044 DOI: 10.1111/j.1365-2249.2004.02599.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 4.6] [Reference Citation Analysis]
288 Honda K, Nakamura K, Matsui N, Takahashi M, Kitamura Y, Mizutani T, Harada N, Nawata H, Hamano S, Yoshida H. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis 2005;11:1044-52. [PMID: 16306766 DOI: 10.1097/01.mib.0000191611.05466.1f] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
289 Alak JIB, Shahbazian M, Huang DS, Wang Y, Darban H, Jenkins EM, Watson RR. Alcohol and Murine Acquired Immunodeficiency Syndrome Suppression of Resistance to Cryptosporidium parvum Infection during Modulation of Cytokine Production. Alcoholism Clin Exp Res 1993;17:539-44. [DOI: 10.1111/j.1530-0277.1993.tb00795.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
290 Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-73. [PMID: 11557635 DOI: 10.1152/ajpregu.2001.281.4.R1264] [Cited by in Crossref: 182] [Cited by in F6Publishing: 107] [Article Influence: 8.7] [Reference Citation Analysis]
291 Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001;49:131-141. [PMID: 11413121 DOI: 10.1136/gut.49.1.131] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 4.0] [Reference Citation Analysis]
292 Garside P, Bunce C, Tomlinson RC, Nichols BL, Mowat AM. Analysis of enteropathy induced by tumour necrosis factor alpha. Cytokine 1993;5:24-30. [PMID: 8485304 DOI: 10.1016/1043-4666(93)90020-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 1.9] [Reference Citation Analysis]
293 Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107:1643-52. [PMID: 7958674 DOI: 10.1016/0016-5085(94)90803-6] [Cited by in Crossref: 469] [Cited by in F6Publishing: 481] [Article Influence: 16.8] [Reference Citation Analysis]
294 Majamaa H, Miettinen A, Laine S, Isolauri E. Intestinal inflammation in children with atopic eczema: faecal eosinophil cationic protein and tumour necrosis factor-alpha as non-invasive indicators of food allergy. Clin Exp Allergy. 1996;26:181-187. [PMID: 8835126 DOI: 10.1111/j.1365-2222.1996.tb00078.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 2.8] [Reference Citation Analysis]
295 Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:593-602. [PMID: 28453766 DOI: 10.1093/ecco-jcc/jjw183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
296 Mowat AM, Widmer MB. A role for IL-4 in immunologically mediated enteropathy. Clin Exp Immunol 1995;99:65-9. [PMID: 7813111 DOI: 10.1111/j.1365-2249.1995.tb03473.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
297 Hobbs SS, Goettel JA, Liang D, Yan F, Edelblum KL, Frey MR, Mullane MT, Polk DB. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G220-G229. [PMID: 21566012 DOI: 10.1152/ajpgi.00383.2010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
298 Jungbeck M, Stopfer P, Bataille F, Nedospasov SA, Männel DN, Hehlgans T. Blocking lymphotoxin beta receptor signalling exacerbates acute DSS-induced intestinal inflammation--opposite functions for surface lymphotoxin expressed by T and B lymphocytes. Mol Immunol 2008;45:34-41. [PMID: 17590442 DOI: 10.1016/j.molimm.2007.05.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
299 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
300 Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402-413. [PMID: 14762776 DOI: 10.1053/j.gastro.2003.11.014] [Cited by in Crossref: 683] [Cited by in F6Publishing: 606] [Article Influence: 37.9] [Reference Citation Analysis]
301 Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T, Yamaguchi T, Morise K, Ieda M, Iokawa H, Ishihara A, Sarai S. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Digest Dis Sci 1995;40:949-59. [DOI: 10.1007/bf02064182] [Cited by in Crossref: 102] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
302 Chang Q, Tepperman BL. The role of protein kinase C isozymes in TNF-alpha-induced cytotoxicity to a rat intestinal epithelial cell line. Am J Physiol Gastrointest Liver Physiol 2001;280:G572-83. [PMID: 11254483 DOI: 10.1152/ajpgi.2001.280.4.G572] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
303 Tran D, Visser J, Pool M, Cuesta M, Hoekman K, Salvador Peña A, Meuwissen S. Enhanced systemic nitric oxide production in inflammatory bowel disease. The Lancet 1993;341:1150. [DOI: 10.1016/0140-6736(93)93166-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
304 Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38:414-420. [PMID: 8675096 DOI: 10.1136/gut.38.3.414] [Cited by in Crossref: 277] [Cited by in F6Publishing: 277] [Article Influence: 10.7] [Reference Citation Analysis]
305 Fish SM, Proujansky R, Reenstra WW. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut. 1999;45:191-198. [PMID: 10403730 DOI: 10.1136/gut.45.2.191] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 5.0] [Reference Citation Analysis]
306 Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease: INTESTINAL IMMUNITY AFTER INFLIXIMAB TREATMENT. Alimentary Pharmacology & Therapeutics 2003;17:703-10. [DOI: 10.1046/j.1365-2036.2003.01487.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
307 Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Cytokines in inflammatory bowel disease. Scand J Gastroenterol 1992;27:897-906. [PMID: 1455185 DOI: 10.3109/00365529209000160] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 1.4] [Reference Citation Analysis]
308 Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003574] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
309 Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004;84:282-291. [PMID: 14767487 DOI: 10.1038/labinvest.3700050] [Cited by in Crossref: 329] [Cited by in F6Publishing: 316] [Article Influence: 18.3] [Reference Citation Analysis]
310 Günther C, Buchen B, Neurath MF, Becker C. Regulation and pathophysiological role of epithelial turnover in the gut. Seminars in Cell & Developmental Biology 2014;35:40-50. [DOI: 10.1016/j.semcdb.2014.06.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
311 Bouma G, Oudkerk Pool M, Scharenberg JG, Kolkman JJ, von Blomberg BM, Scheper RJ, Meuwissen SG, Peña AS. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100. [PMID: 8578170 DOI: 10.3109/00365529509101613] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.7] [Reference Citation Analysis]
312 Baregamian N, Song J, Bailey CE, Papaconstantinou J, Evers BM, Chung DH. Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis. Oxid Med Cell Longev. 2009;2:297-306. [PMID: 20716917 DOI: 10.4161/oxim.2.5.9541] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 8.2] [Reference Citation Analysis]
313 Prager M, Büttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, Büning C. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 2012;27:565-73. [PMID: 22065112 DOI: 10.1007/s00384-011-1345-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
314 Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472. [PMID: 11113067 DOI: 10.1053/gast.2000.20196] [Cited by in Crossref: 324] [Cited by in F6Publishing: 286] [Article Influence: 15.4] [Reference Citation Analysis]
315 Simpson SJ, Holländer GA, Mizoguchi E, Bhan AK, Wang B, Terhorst C. Defects in T-Cell Regulation. Essentials of Mucosal Immunology. Elsevier; 1996. pp. 291-304. [DOI: 10.1016/b978-012394330-9/50024-7] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
316 Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, Sanderson IR, Croft NM. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004;38:270-5. [PMID: 15076624 DOI: 10.1097/00005176-200403000-00007] [Cited by in Crossref: 129] [Cited by in F6Publishing: 109] [Article Influence: 7.6] [Reference Citation Analysis]
317 Leung Y, Panaccione R. Update on ustekinumab for the treatment of Crohn's disease. Gastroenterol Clin North Am 2014;43:619-30. [PMID: 25110262 DOI: 10.1016/j.gtc.2014.05.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
318 Garden OA, Elwood CM, Desport M, Batt RM. In situ hybridization as a technique for the immunological investigation of canine intestine: jejunal expression of IFNgamma and IL10 in Irish setters and beagles. Vet Immunol Immunopathol 1999;70:1-17. [PMID: 10507283 DOI: 10.1016/s0165-2427(99)00036-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
319 Poritz LS, Harris LR, Kelly AA, Koltun WA. Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig Dis Sci. 2011;56:2802-2809. [PMID: 21748286 DOI: 10.1007/s10620-011-1688-9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 9.1] [Reference Citation Analysis]
320 Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-40. [PMID: 8971478 DOI: 10.1016/s1359-6101(96)00026-3] [Cited by in Crossref: 200] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
321 Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995;36:897-901. [PMID: 7615280 DOI: 10.1136/gut.36.6.897] [Cited by in Crossref: 155] [Cited by in F6Publishing: 161] [Article Influence: 5.7] [Reference Citation Analysis]
322 Bücker R, Schumann M, Amasheh S, Schulzke J. Claudins in Intestinal Function and Disease. Elsevier; 2010. pp. 195-227. [DOI: 10.1016/s1063-5823(10)65009-0] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
323 Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. The Lancet 1999;353:459-61. [DOI: 10.1016/s0140-6736(98)03339-x] [Cited by in Crossref: 191] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
324 Sakai T, Kusugami K, Nishimura H, Ando T, Yamaguchi T, Ohsuga M, Ina K, Enomoto A, Kimura Y, Yoshikai Y. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 1998;114:1237-43. [DOI: 10.1016/s0016-5085(98)70430-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
325 Hibi T, Ohara M, Watanabe M, Kanai T, Takaishi H, Hayashi A, Hosoda Y, Ogata H, Iwao Y, Aiso S. Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. Gut 1993;34:788-93. [PMID: 8100205 DOI: 10.1136/gut.34.6.788] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
326 Luissint AC, Nusrat A, Parkos CA. JAM-related proteins in mucosal homeostasis and inflammation. Semin Immunopathol 2014;36:211-26. [PMID: 24667924 DOI: 10.1007/s00281-014-0421-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]